Literature DB >> 28013371

The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts.

Young Hee Shin1, Jeong Jin Min1, Jong-Hwan Lee2, Eun-Hee Kim1, Go Eun Kim1, Myung Hee Kim1, Jeong Jin Lee1, Hyun Joo Ahn1.   

Abstract

Independently of the lipid-lowering effects, statin has been reported to attenuate the development of diabetic cardiomyopathy. However, the effect of statin in glucose-controlled diabetic condition has not been demonstrated. We evaluated the effect of fluvastatin on cardiac function, fibrosis, and angiotensin-converting enzyme-2 (ACE2) expression in glucose-controlled diabetic rats. Male Wistar rats were randomly divided into four groups: control (Group C), diabetes (Group D), diabetes with insulin (Group I), and diabetes with insulin and fluvastatin (Group I+F). Diabetes was induced by a single injection of streptozotocin (65 mg/kg). After 8 weeks, the hearts were extracted following echocardiographic evaluation. Cardiac fibrosis was analyzed using Masson's trichrome stain. Collagens I and III and ACE2 expressions were evaluated by immunohistochemistry and western blot. Group D showed reduced cardiac systolic function compared to the other groups (all P < 0.05). However, diastolic function estimated by E/A ratio was significantly decreased in groups D and I (median: 0.88 and 1.45, respectively) compared to groups C and I+F (2.97 and 2.15) (all P < 0.05). Cardiac fibrosis was more severe in groups D and I than in groups C and I+F (all P < 0.05) on Masson's trichrome stain. On immunohistochemistry, ACE2 expression was significantly decreased only in group D (all P < 0.05). However, collagen I and III showed higher expressions in group D compared to groups C and I+F while no significant difference was observed compared with group I (all P < 0.05). On western blot, collagen I and ACE2 expressions in group D (median: 1.78 and 0.35, respectively) were significantly different from groups C (references: 1) and I+F (0.76 and 1.21) (all P < 0.05), but not from group I (1.19 and 0.92). Our study suggested a combination of fluvastatin and insulin would be more effective than insulin alone in diabetic hearts. However, the exact mechanism remains to be elucidated.

Entities:  

Keywords:  Angiotensin-converting enzyme-2; Diabetic cardiomyopathy; Fluvastatin; Insulin

Mesh:

Substances:

Year:  2016        PMID: 28013371     DOI: 10.1007/s00380-016-0936-5

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  42 in total

Review 1.  Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.

Authors:  James K Liao
Journal:  Am J Cardiol       Date:  2005-09-05       Impact factor: 2.778

2.  Utility of preload alteration in assessment of left ventricular filling pressure by Doppler echocardiography: a simultaneous catheterization and Doppler echocardiographic study.

Authors:  D G Hurrell; R A Nishimura; D M Ilstrup; C P Appleton
Journal:  J Am Coll Cardiol       Date:  1997-08       Impact factor: 24.094

3.  Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor.

Authors:  Qi-Ming Dai; Jing Lu; Nai-Feng Liu
Journal:  Chin Med J (Engl)       Date:  2011-01       Impact factor: 2.628

4.  Diastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short duration.

Authors:  P Di Bonito; S Cuomo; N Moio; G Sibilio; D Sabatini; S Quattrin; B Capaldo
Journal:  Diabet Med       Date:  1996-04       Impact factor: 4.359

5.  Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin.

Authors:  Hiroyuki Ihori; Takashi Nozawa; Mitsuo Sobajima; Takuya Shida; Yasutaka Fukui; Nozomu Fujii; Hiroshi Inoue
Journal:  Heart Vessels       Date:  2015-12-19       Impact factor: 2.037

6.  Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model.

Authors:  K Mizushige; L Yao; T Noma; H Kiyomoto; Y Yu; N Hosomi; K Ohmori; H Matsuo
Journal:  Circulation       Date:  2000-02-29       Impact factor: 29.690

Review 7.  Role of microangiopathy in diabetic cardiomyopathy.

Authors:  Adriana Adameova; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

Review 8.  Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy?

Authors:  S Cosson; J P Kevorkian
Journal:  Diabetes Metab       Date:  2003-11       Impact factor: 6.041

9.  Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus.

Authors:  S Nunoda; A Genda; N Sugihara; A Nakayama; S Mizuno; R Takeda
Journal:  Heart Vessels       Date:  1985-02       Impact factor: 2.037

10.  Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature.

Authors:  Takuya Shida; Takashi Nozawa; Mitsuo Sobajima; Hiroyuki Ihori; Akira Matsuki; Hiroshi Inoue
Journal:  Heart Vessels       Date:  2013-08-25       Impact factor: 2.037

View more
  32 in total

1.  Discovery of antimicrobial compounds targeting bacterial type FAD synthetases.

Authors:  María Sebastián; Ernesto Anoz-Carbonell; Begoña Gracia; Pilar Cossio; José Antonio Aínsa; Isaías Lans; Milagros Medina
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

2.  Age-dependent development of left ventricular wall thickness in type 2 diabetic (db/db) mice is associated with elevated low-density lipoprotein and triglyceride serum levels.

Authors:  Phiwayinkosi V Dludla; M Faadiel Essop; Kwazi B Gabuza; Christo J F Muller; Johan Louw; Rabia Johnson
Journal:  Heart Vessels       Date:  2017-04-09       Impact factor: 2.037

3.  COVID-19, ACE2, and the cardiovascular consequences.

Authors:  Andrew M South; Debra I Diz; Mark C Chappell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-31       Impact factor: 4.733

Review 4.  Dysregulation of the Renin-Angiotensin-Aldosterone System (RAA) in Patients Infected with SARS-CoV-2-Possible Clinical Consequences.

Authors:  Agnieszka Dettlaff-Pokora; Julian Swierczynski
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 5.  Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19.

Authors:  Branka Miličić Stanić; Sydney Maddox; Aline M A de Souza; Xie Wu; Danial Mehranfard; Hong Ji; Robert C Speth; Kathryn Sandberg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-04-13       Impact factor: 3.210

Review 6.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

7.  Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control.

Authors:  Jeong Jin Min; Byung-Seop Shin; Jong-Hwan Lee; Yunseok Jeon; Dae Kyun Ryu; Sojin Kim; Young Hee Shin
Journal:  J Diabetes Res       Date:  2018-02-28       Impact factor: 4.011

8.  In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.

Authors:  Xiao-Jing Zhang; Juan-Juan Qin; Xu Cheng; Lijun Shen; Yan-Ci Zhao; Yufeng Yuan; Fang Lei; Ming-Ming Chen; Huilin Yang; Liangjie Bai; Xiaohui Song; Lijin Lin; Meng Xia; Feng Zhou; Jianghua Zhou; Zhi-Gang She; Lihua Zhu; Xinliang Ma; Qingbo Xu; Ping Ye; Guohua Chen; Liming Liu; Weiming Mao; Youqin Yan; Bing Xiao; Zhigang Lu; Gang Peng; Mingyu Liu; Jun Yang; Luyu Yang; Changjiang Zhang; Haofeng Lu; Xigang Xia; Daihong Wang; Xiaofeng Liao; Xiang Wei; Bing-Hong Zhang; Xin Zhang; Juan Yang; Guang-Nian Zhao; Peng Zhang; Peter P Liu; Rohit Loomba; Yan-Xiao Ji; Jiahong Xia; Yibin Wang; Jingjing Cai; Jiao Guo; Hongliang Li
Journal:  Cell Metab       Date:  2020-06-24       Impact factor: 27.287

Review 9.  Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19.

Authors:  Rafael Silva Lima; Luiz Paulo Carvalho Rocha; Paula Rocha Moreira
Journal:  Cell Biochem Funct       Date:  2021-06-01       Impact factor: 3.963

10.  Preadmission Statin Therapy and Clinical Outcome in Hospitalized Patients With COVID-19: An Italian Multicenter Observational Study.

Authors:  Vincenzo Russo; Angelo Silverio; Fernando Scudiero; Emilio Attena; Antonello D'Andrea; Luigi Nunziata; Guido Parodi; Dario Celentani; Ferdinando Varbella; Stefano Albani; Giuseppe Musumeci; Pierpaolo Di Micco; Marco Di Maio
Journal:  J Cardiovasc Pharmacol       Date:  2021-07-01       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.